Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : The Naked Truth - Big Kahuna a Myth -- Ignore unavailable to you. Want to Upgrade?

To: MythMan who wrote (5679)	9/11/1998 10:30:00 AM
From: yard_man	Read Replies (1) \| Respond to of 86076

Here for some put ideas -- contrarian approach: biz.yahoo.com >>''Our feeling is that U.S. drug stocks are probably the place to be strategically for the next year or possibly two. After that, I don't know,'' said Richard Vietor, pharmaceutical industry analyst at Merrill Lynch in New York. The American Stock Exchange Pharmaceutical Index of 15 large-cap U.S. drug stocks was down 1.7 percent to 646.93 early Thursday as U.S. stocks again moved broadly lower. At that level, the pharma index was 6.3 percent above a four-month low set August 31 when the Dow industrials suffered an historic drop. The broader average of 30 industrial stocks was up only 1.3 percent over the same period by comparison. ''If you're looking for safety in this market, U.S. drug stocks are probably as safe as any sector out there. The only issue is what you should pay for them,'' Vietor said.<<